RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,119 | -1.6% | 22,107 | -3.9% | 0.01% | -16.7% |
| Q2 2023 | $171,832 | +21.7% | 23,003 | +8.7% | 0.01% | +20.0% |
| Q1 2023 | $141,144 | +9.9% | 21,161 | +27.0% | 0.01% | 0.0% |
| Q4 2022 | $128,418 | -44.4% | 16,656 | -23.3% | 0.01% | -50.0% |
| Q3 2022 | $231,000 | +13.2% | 21,707 | -3.8% | 0.01% | +11.1% |
| Q2 2022 | $204,000 | +16.6% | 22,562 | -4.1% | 0.01% | +28.6% |
| Q1 2022 | $175,000 | -24.2% | 23,524 | +50.7% | 0.01% | -22.2% |
| Q4 2021 | $231,000 | +5.5% | 15,606 | +52.3% | 0.01% | -10.0% |
| Q3 2021 | $219,000 | -22.3% | 10,247 | +46.0% | 0.01% | -28.6% |
| Q2 2021 | $282,000 | – | 7,020 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |